Procter & Gamble (PG) Rule 144 Notice — 13,892 Shares Proposed Sale
Rhea-AI Filing Summary
Procter & Gamble (PG) filing a Rule 144 notice shows a proposed sale of company common stock through Morgan Stanley Smith Barney LLC on 08/19/2025. The notice lists two lots: 929 shares with an aggregate market value of $143,906.75 and 12,963 shares with an aggregate market value of $2,008,033.52. The total outstanding shares reported for the issuer are 2,342,371,488, making the proposed sale a vanishingly small fraction of the company’s float.
The securities were acquired on 08/18/2025 as Performance Stock Program awards from The Procter & Gamble Company and payment/consideration is listed as NA. The filer certifies there are no known undisclosed material adverse facts and reports no securities sold by the person in the past three months.
Positive
- Complete Rule 144 disclosure including broker, share counts, aggregate market values, acquisition details, and certification
- No reported sales by the person in the past three months, per the filing
- Transaction size is immaterial relative to the issuer's outstanding shares (approximately 0.0006%)
Negative
- Selling one day after acquisition (acquired 08/18/2025; proposed sale 08/19/2025) may attract investor attention regarding timing
- Form does not state whether the sale is governed by a Rule 10b5-1 trading plan
Insights
TL;DR: Routine Rule 144 sale of recently issued performance shares; size is immaterial to company capitalization.
The filing documents a proposed sale of 13,892 common shares via Morgan Stanley Smith Barney LLC on 08/19/2025, following acquisition on 08/18/2025 under a Performance Stock Program. Given the issuer's reported outstanding shares of 2,342,371,488, the transaction represents approximately 0.0006% of outstanding shares and is immaterial to market capitalization or liquidity. No prior sales by the seller in the last three months are reported, and the filer affirms no undisclosed material adverse information. This is consistent with routine insider monetization of compensation awards.
TL;DR: Compliance-oriented disclosure that appears complete for a Rule 144 notice; timing of sale is notable but not necessarily problematic.
The form provides required fields: broker identity, share counts, aggregate market values, acquisition date and nature (Performance Stock Program Award), and a certification regarding material information. The proximity of acquisition (08/18/2025) to the proposed sale date (08/19/2025) is a factual detail investors may notice; however, the filing includes the standard attestation and shows no other recent sales. From a governance perspective, the document meets Rule 144 disclosure elements but does not indicate whether a 10b5-1 plan governs the sale.